Similar articles

Abstract: The present study was undertaken to evaluate the endometrial secretion and synthesis of proteins in hamsters that were subjected to ovarian stimulation with or without GnRH agonist (Leuprolide Acetate, LA). The results of protein resolution revealed that the molecular weight of the proteins increased from 31D to 66D, while the intensities of photographed protein bands in the hamsters treated with LA and pregnant mare's serum gonadotropin (PMSG) were less than that in those treated with PMSG alone. The amounts of low and medium weights (31kD and 45kD) proteins newly synthesized in LA+PMSG group and saline group (control) were significantly higher than that in PMSG group. The synthesized and secreted proteins in groups LA and control were similar. The data suggested that a physiologic endometrial protein secretory and synthetic change with GnRH agonist regarcded as a possible cause of the higher pregnancy rate in in vitro fertilization. The degree of endometrial secretion and synthesis varied considerably with the type of ovarian stimulation used.

[1]Balasch, J., Jove, I., Marquez, M. et al., 1991. Hormonal and histological evaluation of the luteal phase after combined GnRH agonist /gonadotropin treatment for superovulation and luteal phase support in in-vitro fertilization. Hum Reprod, 6: 914-917.

[2]Biljan, M.M. and Tan, S.L., 1997. GnRH ago nists in gonadotropin ovulation induction: characteristicsof long regimens. Presented at the Proceedings of the 2nd World Conference on Ovulation Induction. Bologna, p.75-82.

[3]Daya, S., 1997. Optimal protocol for gonadotropin releasing hormone agonist use in ovarian stimulation. Presented at 10th World Congress on In: Vitro Fertilization and Assisted Conception. Vancouver, p.405-410.

[4]Forman, R., Fries, N., Testart, J. et al., 1988. Evidence of an advance of elevated serum estradiol concentrations on embryo implantation. Fertil Steril, 49:118-122.

[5]Fossum, G.T., Davidsom, A., Paulson, R. J. et al., 1989. Ovarian hyperstimulation inhibits embryo implantation in the mouse. J In Vitro Fert Embryo Transf, 6:7-11.

[6]Gonen, Y., Casper, R. F., Tacobson, W. et al., 1989. Endomentrial thickness and growth during ovarian stimulation: a possible predictor of implantation in in vitro fertilization. Fertil Steril, 52:446-451.

[7]Lopata, A., 1996. Implantation of the human embryo. Hum Reprod, 11 (suppl.): 175-184.

[8]Neveu, S., Hedon B,.Bringer, J. et al., 1987. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril, 47:639.

[9]Oyesanya, O.A., Teo, S.K., Quah, E. et al., 1995. Pituitary down-regulation prior to in-vitro ertilization and embryo transfer: a comparison between a single dose Zoladex depot and multiple daily doses of suprefact. Hum Reprod., 10:1042-1044.

[10]Parinaud, J., Oustry, P., Perineau, M. et al., 1992. Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertil Steril, 57:1265.

[11]Speirs, A. L., Baker, H.W.G. and Abdullah, N., 1996. Analysis of factors affecting embryo implantation. Hum Reprod., 11(suppl.): 187.

[12]Tan, S.L., Royston, P. Campbell, S. et al., 1992. Cumulative conception and livebirth rates after in vitro fertilization. Lancet, 339: 1390-1394.